| First Author | Chen Y | Year | 2023 |
| Journal | Cell Death Dis | Volume | 14 |
| Issue | 2 | Pages | 85 |
| PubMed ID | 36746922 | Mgi Jnum | J:344601 |
| Mgi Id | MGI:7433322 | Doi | 10.1038/s41419-023-05613-6 |
| Citation | Chen Y, et al. (2023) Restoration of lipid homeostasis between TG and PE by the LXRalpha-ATGL/EPT1 axis ameliorates hepatosteatosis. Cell Death Dis 14(2):85 |
| abstractText | Converting lipid disturbances in response to energy oversupply into healthy lipid homeostasis is a promising therapy to alleviate hepatosteatosis. Our clinical studies found that a further elevation of triglyceride (TG) in obese patients with the body mass index (BMI) greater than 28 was accompanied by a further reduction of phosphatidylethanolamine (PE). Shorter survival and poor prognosis were shown for the patients with high TG and low PE levels. Liver X receptor alpha (LXRalpha) knockout mice aggravated high-fat diet (HFD)-induced obesity and lipid disorders, making the TG enrichment and the PE decrease more pronounced according to the liver lipidomics analysis. The RNA-seq from mice liver exhibited that these metabolism disorders were attributed to the decline of Atgl (encoding the TG metabolism enzyme ATGL) and Ept1 (encoding the PE synthesis enzyme EPT1) expression. Mechanistic studies uncovered that LXRalpha activated the ATGL and EPT1 gene via direct binding to a LXR response element (LXRE) in the promoter. Moreover, both the supplement of PE in statin or fibrate therapy, and the LXRalpha inducer (oridonin) ameliorated cellular lipid deposition and lipotoxicity. Altogether, restoration of lipid homeostasis of TG and PE via the LXRalpha-ATGL/EPT1 axis may be a potential approach for the management of hepatosteatosis and metabolic syndrome. |
